Phenylethanolamine N-methyltransferase
(PNMT)
catalyzes the S-adenosyl-l-methionine (SAM)-dependent
methylation of norepinephrine to form epinephrine. Epinephrine is
implicated in the regulation of blood pressure, respiration, Alzheimer’s
disease, and post-traumatic stress disorder (PTSD). Transition-state
(TS) analogues bind their target enzymes orders of magnitude more
tightly than their substrates. A synthetic strategy for first-generation
TS analogues of human PNMT (hPNMT) permitted structural analysis of
hPNMT and revealed potential for second-generation inhibitors [MahmoodiN.
Mahmoodi, N.
J. Am. Chem. Soc.20201421422214233. A
second-generation TS analogue inhibitor of PNMT was designed, synthesized,
and characterized to yield a Ki
value
of 1.2 nM. PNMT isothermal titration calorimetry (ITC) measurements
of inhibitor 4 indicated a negative cooperative binding
mechanism driven by large favorable entropic contributions and smaller
enthalpic contributions. Cell-based assays with HEK293T cells expressing
PNMT revealed a cell permeable, intracellular PNMT inhibitor with
an IC50 value of 81 nM. Structural analysis demonstrated
inhibitor 4 filling catalytic site regions to recapitulate
both norepinephrine and SAM interactions. Conformation of the second-generation
inhibitor in the catalytic site of PNMT improves contacts relative
to those from the first-generation inhibitors. Inhibitor 4 demonstrates up to 51,000-fold specificity for PNMT relative to
DNA and protein methyltransferases. Inhibitor 4 also
exhibits a 12,000-fold specificity for PNMT over the α2-adrenoceptor.